Acuitive Technologies Launches New Tendon Fixation Device for Sports Medicine

Acuitive Technologies Launches New Tendon Fixation Device for Sports Medicine

Article content

Citrelock® Differentiated Biomaterial and Design Features

Advertisement 2

Story continues below

Article content

ALLENDALE, N.J., June 29, 2023 (GLOBE NEWSWIRE) — Acuitive Technologies, Inc. (Acuitive) today announced the first surgical use of its Citrelock® ACL Tendon Fixation Device. The new ACL device provides surgeons a differentiated design via a tendon-friendly spiral thread featuring a next-generation resorbable technology, known as Citregen, that has unique molecular and mechanical properties for orthopedic surgical applications.

Article content

Robin Gehrmann M.D.

Robin Gehrmann M.D., President of the New Jersey Orthopedic Society and Clinical Assistant Professor of Orthopedics, Rutgers-New Jersey Medical School, successfully implanted the first Citrelock ACL Tendon Fixation Device today.

“By leveraging Citregen’s unique material properties, the Citrelock Tendon Fixation Device introduces design features to ease insertion and secure fixation without damaging the tendon during placement,” said Robin Gehrmann, MD, orthopedic surgeon. “It has been exciting to participate in the development of a completely novel biomaterial for use in orthopedic applications. I believe this unique material technology will improve tendon fixation as it participates in the natural healing process while avoiding chronic inflammation seen with other biodegradable devices.”

See also  Goldman's Global Economic Outlook Through 2075

Article content

Advertisement 3

Story continues below

Article content

CITRELOCK ACL Tendon Fixation Device

The Citrelock ACL Tendon Fixation Device offers surgeons:

  • Biomimetic material composition to match the native bone inorganic content
  • A novel soft spiral thread design to avoid tendon laceration
  • A compressive strength similar to cortical bone and a modulus similar to trabecular bone
  • Elastomeric properties for improved pull-out strength
  • A controlled resorption rate to mitigate chronic inflammation

“Our customers are looking for a more predictable and effective bioresorbable material than what is currently on the market,” said Rui Ferreira, VP of Product Development, Acuitive. “The Citrelock ACL Tendon Fixation Device helps fill that clinical need with its innovative material technology and unique design. Citrelock ACL System is an exciting addition to Acuitive’s portfolio and is the first in a series of new products we will be launching with a focus on the Sports Medicine market.”

Advertisement 4

Story continues below

Article content

About Acuitive
Acuitive is a medical technology company developing innovative biomaterials and orthopedic devices that participate in the natural healing process of musculoskeletal tissues while addressing the shortcomings of current biomaterials. Together with its surgeon customers, Acuitive is driven to make healthcare outcomes better for our patients. More information is available at www.acuitivetech.com.

A surgeon must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Acuitive does not dispense medical advice and recommends that surgeons be trained in the use of any product before using it in surgery.

See also  The Supreme Court gave abortion-rights supporters a win, but those on both sides of the debate say the battle is far from over

Advertisement 5

Story continues below

Article content

A surgeon must always refer to the package insert, product label and/or instructions for use before using any of Acuitive’s products. Please contact Acuitive directly if you have questions about the availability of products in your area.

Media Contact
Michael McCarthy
Acuitive Technologies, Inc.
mmccarthy@acuitivetech.com
201.661.2680

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/ff9adec6-7eed-4ffb-8840-7e1dba73176b

https://www.globenewswire.com/NewsRoom/AttachmentNg/1a4edd69-9d16-40e8-aa23-b204fcb45bfe

Article content

Comments

Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notifications—you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.

Join the Conversation

Leave a Reply

Your email address will not be published. Required fields are marked *